Subscribe To

Price Alert Latest News Economic Calendar News

IBOGF / Universal Ibogaine says 2023 will be pivotal year for the company and Canadians seeking ibogaine treatment

Universal Ibogaine Inc (TSX-V:IBO) said it has laid the groundwork during 2022 to enter the new year positioned to advance its planned clinical trial involving semi-synthesized Ibogaine HCL (ibogaine hydrochloride) for the treatment of opioid use disorder. In a year-end summary of its 2022 accomplishments, Universal Ibogaine CEO Nick Karos noted that 2022 was a busy year of behind-the-scenes activity laying the foundations with Health Canada in preparation for the company's planned clinical trial application and sourcing the related ibogaine drug supply. Read More

Demo Live Account See Partner Details

Content Topics

Universal

Ibogaine

Says

2023

Will

Pivotal

Year

Company

Canadians

Seeking

Treatment

Stock

IBOGF

Posted: Jan 4 2023, 11:46

Author Name: Proactive Investors

IBOGF News

By Proactive Investors
January 4, 2023

Universal Ibogaine says 2023 will be pivotal year for the company and Canadians seeking ibogaine treatment

Universal Ibogaine Inc (TSX-V:IBO) said it has laid the groundwork during 2022 to enter the new year positioned to advance its planned clinical trial

By Proactive Investors
December 1, 2022

Universal Ibogaine closes private placement, announces potential C$5M offering of convertible debt securities and shares

Universal Ibogaine Inc (TSX-V:IBO) said it has closed its previously announced non-brokered private placement of convertible notes for the aggregate p

By Proactive Investors
April 29, 2022

Universal Ibogaine retains co-founder Shayne Nyquvest as capital markets advisor

Universal Ibogaine Inc (TSX-V:IBO) told investors that it has retained Shayne Nyquvest in a consulting role as capital markets advisor. Nyquvest, a

By Proactive Investors
April 8, 2022

Universal Ibogaine eyeing resumption of operations after Kelburn Recovery Centre flood

Universal Ibogaine Inc (TSX-V:IBO) told investors that it is looking to "resume on-site operations" after temporarily closing the Kelburn Recovery Cen

Risk Disclosure:

Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
We would like to remind you that the data contained in this website is not necessarily real-time nor accurate.
The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. We and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of us and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website. We may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.